Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat

Aim: Multiple myeloma (MM) is a hematological malignancy of antibody-producing mature B cells or plasma cells. The proteasome inhibitor, bortezomib, was the first-in-class compound to be FDA approved for MM and is frequently utilized in induction therapy. However, bortezomib refractory disease is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Tiewei, Kiser, Kendall, Grasse, Leslie, Iles, Lakesla, Bartholomeusz, Geoffrey, Samaniego, Felipe, Orlowski, Robert Z., Chandra, Joya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653980/
https://www.ncbi.nlm.nih.gov/pubmed/34888496
http://dx.doi.org/10.20517/cdr.2021.44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653980/
https://www.ncbi.nlm.nih.gov/pubmed/34888496
http://dx.doi.org/10.20517/cdr.2021.44

Ejemplares similares